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1. INTRODUCTION {#all14137-sec-0006}
===============

Airway hyperresponsiveness (AHR), pulmonary inflammation, eosinophilia, and mucus hyperplasia are hallmarks of allergic asthma. Indeed, chronic disease is driven predominantly by T~H~2 immune responses with pathology largely caused by IL‐4 and IL‐13 signaling, which share a common pleiotropic receptor subunit, interleukin 4 receptor alpha (IL‐4Rα).[1](#all14137-bib-0001){ref-type="ref"}, [2](#all14137-bib-0002){ref-type="ref"}, [3](#all14137-bib-0003){ref-type="ref"}, [4](#all14137-bib-0004){ref-type="ref"} The IL‐4/IL‐13 axis has been a target for allergic asthma treatment; however, anti‐T~H~2‐based therapies for asthma have seen limited success in clinical trials.[4](#all14137-bib-0004){ref-type="ref"}, [5](#all14137-bib-0005){ref-type="ref"}, [6](#all14137-bib-0006){ref-type="ref"} The therapy conundrum is further compounded by phenotypic heterogeneity among asthma cases, limited treatment options for steroid‐resistant cases, and possible non‐T~H~2 inflammatory mechanisms involved in asthma pathogenesis.[7](#all14137-bib-0007){ref-type="ref"}, [8](#all14137-bib-0008){ref-type="ref"}, [9](#all14137-bib-0009){ref-type="ref"}, [10](#all14137-bib-0010){ref-type="ref"}, [11](#all14137-bib-0011){ref-type="ref"} However, targeting T~H~2‐type inflammation still remains a promising therapeutic approach for a large proportion of carefully stratified asthma patients.[9](#all14137-bib-0009){ref-type="ref"}

Key in the IL‐4/IL‐13 axis is the IL‐4Rα signaling which has been identified as a potential target for asthma therapies.[12](#all14137-bib-0012){ref-type="ref"}, [13](#all14137-bib-0013){ref-type="ref"}, [14](#all14137-bib-0014){ref-type="ref"} Deficiency of IL‐4Rα in allergen‐sensitized mice shows reduced allergen‐induced symptoms such as AHR, eosinophilia, and mucus hyperplasia in vivo.[15](#all14137-bib-0015){ref-type="ref"}, [16](#all14137-bib-0016){ref-type="ref"}, [17](#all14137-bib-0017){ref-type="ref"} We and others have also illustrated various cell‐specific roles of IL‐4Rα signaling during the development of allergic disease pathology.[11](#all14137-bib-0011){ref-type="ref"}, [18](#all14137-bib-0018){ref-type="ref"}, [19](#all14137-bib-0019){ref-type="ref"}, [20](#all14137-bib-0020){ref-type="ref"}, [21](#all14137-bib-0021){ref-type="ref"} However, limited successful anti‐T~H~2‐based treatments for asthma calls for better understanding of the mechanisms involved in successful therapy. Hence, we investigated in vivo requirements of IL‐4Rα signaling after allergic sensitization prior to the onset of disease as well as after T~H~2 pulmonary allergic airway lung inflammation. We hypothesized that temporal significance of IL‐4Rα signaling might highlight its prophylactic and therapeutic relevance, especially as most patients are diagnosed only after established exacerbations.[22](#all14137-bib-0022){ref-type="ref"}, [23](#all14137-bib-0023){ref-type="ref"} Resurgence of side effects such as T~H~17 responses has been a concern for anti‐T~H~2 targeted therapies.[4](#all14137-bib-0004){ref-type="ref"}, [5](#all14137-bib-0005){ref-type="ref"}, [6](#all14137-bib-0006){ref-type="ref"}, [24](#all14137-bib-0024){ref-type="ref"}, [25](#all14137-bib-0025){ref-type="ref"}, [26](#all14137-bib-0026){ref-type="ref"}, [27](#all14137-bib-0027){ref-type="ref"}, [28](#all14137-bib-0028){ref-type="ref"}

We developed a TAM‐induced, conditional IL‐4Rα knockdown mouse model (Rosa^creERT2^IL‐4Rα^−/lox^) and sought to investigate the temporal role of IL‐4Rα receptor signaling during the effector phase (therapeutic) and priming/sensitization phase (prophylactic) of allergic asthma. Rosa^creERT2^IL‐4Rα^−/lox^, IL‐4Rα^−/lox^, and IL‐4Rα^−/−^ mice were sensitized with OVA/alum complex intraperitoneally and challenged intranasally with OVA to induce allergic airway disease. Temporal deletion of IL‐4Rα chain after sensitization phase prevented disease development, whereas temporal deletion during the effector phase reduced most disease parameters, such as AHR, eosinophilia, as well as goblet cell metaplasia. Unexpectedly, temporal deletion of IL‐4Rα signaling in both prophylactic and therapeutic models did not develop T~H~17‐type and neutrophilic airway inflammation, a phenotype completely different to global deletion of IL‐4Rα. We, thus, conclude that abrogation of IL‐4Rα signaling after allergic sensitization would have significant therapeutic benefit for T~H~2 type asthma without inducing potentially detrimental T~H~17 responses.

2. METHODS {#all14137-sec-0007}
==========

2.1. Mice {#all14137-sec-0008}
---------

We generated an inducible IL‐4Rα deletion mouse*,* Rosa^creERT2^IL‐4Rα^−/lox^ [29](#all14137-bib-0029){ref-type="ref"} on a BALB/c background by intercrossing transgenic Rosa^creERT2^IL‐4Rα^−/lox^C57BL/6 mice[29](#all14137-bib-0029){ref-type="ref"} with IL‐4Rα*^lox/lox^* BALB/c mice (Figure [S1](#all14137-sup-0001){ref-type="supplementary-material"}). IL‐4Rα^−/lox^ [30](#all14137-bib-0030){ref-type="ref"}and IL‐4Rα^−/−^ [31](#all14137-bib-0031){ref-type="ref"}mice on a BALB/c background were used as control animals. Eight‐ to twelve‐week‐old mice were used for the experiments and housed in independently ventilated cages under specific pathogen‐free conditions in the University of Cape Town Animal Facility. Animal procedures were approved by the University of Cape Town Animal Ethics Committee (reference number, 015/009).

2.2. Models of allergic airway disease {#all14137-sec-0009}
--------------------------------------

### 2.2.1. Prophylactic model: Postsensitization IL‐4Rα knockdown in ovalbumin‐induced allergic airway disease {#all14137-sec-0010}

Mice were sensitized intraperitoneally with (50 µg in 200 µL) of ovalbumin (OVA) adsorbed to 0.65% alum (Sigma‐Aldrich) on days 0, 7, 14.[32](#all14137-bib-0032){ref-type="ref"} The TAM and oil treatment was done by oral gavage of 100 µL of 2.5 mg/d tamoxifen solubilized in vegetable oil (OIL) or 100 µL of vegetable oil, respectively, on days 15, 16, 17, 18. On days 23, 24, 25, mice were intranasally challenged with 100 µg of OVA under anesthesia with anaesthetized with ketamine (Anaket‐V; Centaur Labs) and xylazine (Rompun; Bayer) as previously described.[32](#all14137-bib-0032){ref-type="ref"} AHR was measured on day 26. After the procedure, mice were euthanized with halothane and tissue samples collected for analysis.

### 2.2.2. Therapeutic model: Posteffector phase IL‐4Rα knockout in ovalbumin‐induced allergic airway disease {#all14137-sec-0011}

Mice were sensitized intraperitoneally with (50 µg in 200 µL) of OVA/alum on days 0, 7, 14. On days 23, 24, 25, mice were intranasally challenged with 100 µg of OVA under anesthesia. TAM and OIL treatment was done on days 26, 27, 28, 29. Mice were intranasally challenged again on days 34, 35, 36, and AHR was measured on day 37. After the procedure, mice were euthanized and tissue samples were collected for analysis.

2.3. Lung function measurements {#all14137-sec-0012}
-------------------------------

Airway resistance and elastance of the whole respiratory system (airways, lung chest wall) after intranasal challenge was determined by forced oscillation measurements as described previously[32](#all14137-bib-0032){ref-type="ref"} with the Flexivent system (SCIREQ) by using the single compartment ("snapshot") perturbation. Measurements were carried out on mice with increasing doses of acetyl‐ß‐methylcholine (methacholine, Sigma‐Aldrich) treatment. Differences in the dose‐response curves were analyzed by repeated‐measures ANOVA with the Bonferroni post‐test. Only mice with acceptable measurements for all doses (coefficient of determination \> 0.90) were included in the analysis.

2.4. Analysis of cell populations by flow cytometry {#all14137-sec-0013}
---------------------------------------------------

Bronchoalveolar lavage (BAL) cells were obtained as previously described.[19](#all14137-bib-0019){ref-type="ref"} Single‐cell suspensions were prepared from lymph nodes in Iscove\'s modified Dulbecco\'s medium (IMDM) (Gibco) by passing them through 40‐µm filter. To obtain single‐cell suspensions from lung tissues, a left lobe lung was digested for 1 hour at 37°C in RPMI (Gibco, Paisley, United Kingdom) containing 13 mg/mL DNase I (Roche) and 50 U/mL collagenase IV (Gibco) and passed through 70‐µm filter. Single cells were then blocked with 24G2 for 30 minutes at 4°C, followed by surface staining with fluorophore‐conjugated antibodies for 30 minutes at 4°C in the dark.

Antibodies used in these experiments included phycoerythrobilin (PE)‐conjugated anti‐Siglec‐F (clone, E50‐2440), and anti‐CD124 (IL‐4Rα, clone, M‐1), FITC‐conjugated anti‐Gr‐1 (clone, RB6‐8C5), PerCPCy5.5‐conjugated anti‐Ly6C (clone, AL‐21), ‐CD45.1 (clone, A20), Allophycocyanin (APC)‐conjugated anti‐CD11c (clone, HL3), V450‐conjugated anti‐CD11b (clone, M1/70), AlexaFlour 700‐conjugated anti‐CD3ε (clone, 145‐2C11), V500‐anti‐CD4 (clone, RM4‐5) and anti‐B220 (clone, RA3‐6B2), APC‐Cy7‐conjugated anti‐CD19 (clone, 1D3), and anti‐CD8 (clone, 53‐6.7) were purchased from BD Biosciences, PE‐Cy7 anti‐F4/80 (clone, BM8), AlexaFlouro 700‐conjugated anti‐MHC II (clone, M5/114), and live/dead fixable yellow stain (Qdot605 dead cell exclusion dye) were purchased from eBiosciences. For intracellular cytokine staining, surface‐stained cell suspensions were fixed in 2% PFA, permeabilized with 0.5% saponin buffer, and stained with PE‐conjugated p‐STAT6 (clone, J71‐773.58.11 BD Biosciences). Cells were acquired using Fortessa (BD Biosciences), and data were analyzed with FlowJo version 10 software (TreeStar).

2.5. Histology and immunohistochemistry {#all14137-sec-0014}
---------------------------------------

Lungs were fixed in 4% formaldehyde/PBS and embedded in paraffin. Tissue sections were stained with periodic acid‐Schiff (PAS) for mucus secretion, hematoxylin and eosin (H&E) staining for inflammation. Image analysis was performed on NIS Elements (Nikon Instruments). Mucus quantification was carried out using the automated NIS Elements software by defining regions of interest (ROIs) which are the individual bronchioles on cut lung sections to be analyzed for mucus staining and using threshold quantification of the mucus stain in the specific ROIs NIS Elements (Nikon Instruments). Area of staining is defined as total area of mucus secretion per area of bronchiole epithelial lining. Lung sections from individual mice were assessed, and data from 3 experiments were pooled (n = 4‐6 mice per experiment).

2.6. Antibody and cytokine ELISAs {#all14137-sec-0015}
---------------------------------

Antibody ELISAs were carried out as previously described [19](#all14137-bib-0019){ref-type="ref"} using 1 mg/mL OVA to coat for specific IgE and 0.5 mg/mL to coat for IgGs. For in vitro cytokine production analysis, single‐cell suspensions were prepared from mediastinal lymph nodes of OVA‐treated and littermate control mice.[19](#all14137-bib-0019){ref-type="ref"} Cells (2 × 10^5^ cells, in 200 µL) were incubated for 5 days in IMDM/10% FCS (Delta Bioproducts) in 96‐well plates. Cells were either stimulated with OVA (50 µg/mL) or anti‐CD3 (10 µg/mL) and supernatants were collected after incubation period. Concentrations of IL‐2, IL‐4, IL‐5, IFN‐*γ*, (BD Biosciences), IL‐13 (R&D Systems), IL‐17, and IL‐23 (BioLegend) were measured using ELISA assays according to the manufacturer\'s protocol.

2.7. Statistical analysis {#all14137-sec-0016}
-------------------------

*P* values were calculated in GraphPad Prism 6 (GraphPad Software, Inc) by using nonparametric Mann‐Whitney Student\'s *t* test or two‐way ANOVA with Bonferroni\'s post‐test for multiple comparisons, and results are presented as SE of the mean. Differences were considered significant if *P* was \<.05.

3. RESULTS {#all14137-sec-0017}
==========

3.1. Characterization of IL‐4Rα expression in Rosa^creERT2^IL‐4Rα^−^ ^/lox^ mice {#all14137-sec-0018}
--------------------------------------------------------------------------------

Inducible Rosa^creERT2^IL‐4Rα^−/lox^ mouse strain has been previously characterized on a C57BL/6 background strain by our laboratory and shown to have impaired expression of IL‐4Rα on lung and lymph node tissue upon TAM treatment.[33](#all14137-bib-0033){ref-type="ref"} Here, we characterized IL‐4Rα expression in Rosa^creERT2^IL‐4Rα^−/lox^ mouse strain on the BALB/c background under OVA‐induced allergic asthma. The tamoxifen‐induced deletion of IL‐4Rα lasts for more than 16 weeks after 4 days of tamoxifen instillation by oral gavage with no homeostatic imbalance.[33](#all14137-bib-0033){ref-type="ref"} We induced deletion of IL‐4Rα in two models, prophylactic (where mice were fed TAM orally after sensitization before acute challenge with OVA) and therapeutically (where mice were fed TAM orally after sensitization and acute challenge with OVA) (Figure [1](#all14137-fig-0001){ref-type="fig"}A). Efficient knockdown of IL‐4Rα in both lung and mediastinal lymph node (mLN) tissue after TAM treatment compared to vehicle‐treated mice was observed (Figure [1](#all14137-fig-0001){ref-type="fig"}B,C). We further evaluated cell type--specific deletion of IL‐4Rα and found significantly reduced expression in inflammatory cells such as CD4^+^ T cells, B cells, and dendritic cells (DCs), but not macrophages in lung tissue of TAM‐treated mice compared to the OIL‐treated littermate controls (Figure [1](#all14137-fig-0001){ref-type="fig"}D,E). Expression levels of IL‐4Rα after TAM knockdown were similar to those observed in IL‐4Rα global knockout mice (Figure [1](#all14137-fig-0001){ref-type="fig"}B‐E). We therefore concluded that IL‐4Rα was efficiently knocked down upon treatment with TAM.

![Prophylactic and therapeutic inducible deletion of IL‐4Rα in OVA‐induced allergic airway inflammation. A, Schematic diagram of IL‐4Rα deletion using the tamoxifen (TAM)‐inducible mouse model (ROSA^creERT2^IL‐4Rα^−/lox^ mice) in a prophylactic (top panel) and therapeutic model (bottom panel). Mice were fed TAM (2.5 mg) orally for 4 d either after sensitization (prophylactic) or after first challenge (therapeutic). B, IL‐4Rα expression in different organs including bronchoalveolar lavage fluid (BALF), lung, and mediastinal lymph nodes (mLNs) in the prophylactic model. C, IL‐4Rα expression in different organs including BALF, lung, and mLNs in the therapeutic model. D, IL‐4Rα expression in different lung cell types including B cells (CD19^+^MHCII^+^), T cells (CD3^+^ MHCII^−^CD11c^−^), CD4^+^ T cells (CD3^+^CD4^+^MHCII^−^CD11c^−^), dendritic cells (CD11c^high^SiglecF^low^ MHCII^hi^), and alveolar macrophages (CD11c^hi^SiglecF^hi^ MHCII^low^) in a prophylactic model. E, IL‐4Rα expression in different lung cell types including B cells (CD19^+^MHCII^+^), T cells (CD3^+^MHCII^−^CD11c^−^), CD4^+^ T cells (CD3^+^CD4^+^MHCII^−^CD11c^−^), dendritic cells (CD11c^high^ SiglecF^low^ MHCII^hi^), and alveolar macrophages (CD11c^hi^SiglecF^hi^ MHCII^low^) in a therapeutic model. Data shown mean ± SDs from 1 representative experiment of 3, n = 5. Significant differences to *IL‐4Ra* ^−/−^ OVA: \**P* \< .05, \*\**P* \< .01, \*\*\**P* \< .001](ALL-75-1347-g001){#all14137-fig-0001}

3.2. Knockdown of the IL‐4Rα signaling prophylactically prevented the development of AHR and airway inflammation {#all14137-sec-0019}
----------------------------------------------------------------------------------------------------------------

Mice deficient in IL‐4Rα are protected from OVA‐induced allergic airway disease.[1](#all14137-bib-0001){ref-type="ref"} Here, we explored the temporal requirement of this signaling pathway postsensitization with OVA/alum. We assessed AHR after OVA challenge and found TAM‐Rosa^creERT2^IL‐4Rα^−/lox^ mice to have significantly reduced airway resistance and elastance compared to the OIL‐Rosa^creERT2^IL‐4Rα^−/lox^ littermate controls (Figure [2](#all14137-fig-0002){ref-type="fig"}A). We also observed significantly increased resistance and elastance in OVA‐challenged and OIL‐Rosa^creERT2^IL‐4Rα^−/lox^ when compared to PBS‐challenged control mice. This demonstrated that deletion of IL‐4Rα after sensitization prevented the development of AHR following allergen challenge.

![Prophylactic deletion of the IL‐4Rα restores normal lung function and reduces allergic airway inflammation. Mice (ROSA^cre\ ERT2^IL‐4Rα^−/lox^) were sensitized with ovalbumin (OVA)/Alum on days 0, 7, and 14 and fed TAM or OIL on days 15 to 18 and challenged with OVA on days 23‐25. Analysis was done on day 26. A, Airway resistance and airway elastance were measured with increasing doses of methacholine (0‐40 mg/mL). B, Total bronchoalveolar lavage fluid cells. C, Total lung cells. D, Total number of neutrophils (CD11c^low^CD11b^high^Ly6G^high^) and eosinophils (CD11c^low^ CD11b^high^ Ly6G^low^ SiglecF^hi^) in the BALF were stained and analyzed by flow cytometry. E, Histology analyses of lung sections (magnification ×200), stained with hematoxylin and eosin (H&E) (bottom) and periodic acid‐Schiff (PAS) (top). F, Automated quantification of the area (μm^2^) of mucus staining per analyzed bronchiole epithelial lining was carried out using NIS elements imaging software. Shown is mean ± SDs from one representative of 3 independent experiments (n = 5‐8). Significant differences are described as: \**P* \< .05, \*\**P* \< .01, \*\*\**P* \< .001](ALL-75-1347-g002){#all14137-fig-0002}

We measured total numbers of infiltrating cells, eosinophils, and neutrophils in the BAL fluid and lung tissue and found that total cells and eosinophils were reduced in TAM‐Rosa^creERT2^IL‐4Rα^−/lox^ mice compared to OIL‐Rosa^creERT2^IL‐4Rα^−/lox^ mice (Figure [2](#all14137-fig-0002){ref-type="fig"}B‐D). We observed increased neutrophil infiltration in IL‐4Rα^−/−^ mice, which was absent in TAM‐Rosa^creERT2^IL‐4Rα^−/lox^ mice (Figure [2](#all14137-fig-0002){ref-type="fig"}D). Furthermore, we observed reduced mucus hypersecretion (Figure[2](#all14137-fig-0002){ref-type="fig"}E,F) and lung inflammation (Figure [2](#all14137-fig-0002){ref-type="fig"}E) in TAM‐Rosa^creERT2^IL‐4Rα^−/lox^ mice compared to OIL‐Rosa^creERT2^IL‐4Rα^−/lox^ mice. Taken together, these data demonstrate that IL‐4Rα‐dependent signaling postsensitization is important in regulating airway inflammation and that IL‐4Rα‐dependent signaling prior to sensitization may contribute to airway neutrophilia.

3.3. IL‐4Rα signaling is necessary for inducing a T~H~2 allergic airway immune response in a prophylactic model {#all14137-sec-0020}
---------------------------------------------------------------------------------------------------------------

We measured T~H~2 cytokines after stimulation of mLNs with anti‐CD3 (Figure [3](#all14137-fig-0003){ref-type="fig"}A) or OVA antigen (Figure [3](#all14137-fig-0003){ref-type="fig"}B) in prophylactic model. Temporal deletion of IL‐4Rα in a prophylactic model significantly reduced IL‐4, IL‐5, and IL‐13 production in TAM‐Rosa^creERT2^IL‐4Rα^−/lox^ mice compared to OIL‐Rosa^creERT2^IL‐4Rα^−/lox^ mice (Figure [3](#all14137-fig-0003){ref-type="fig"}A,B). This was consistent with reduced pathology showing that even temporal deletion of IL‐4Rα has significant impact in TH2 allergic airway response, a phenotype we have mainly observed in global deletion of the gene. We analyzed phosphorylation of downstream transcription factor, signal transducer, and activator of transcription 6 (STAT6) by flow cytometry in lung, mLNs, and lung CD4^+^ T cells (Figure [3](#all14137-fig-0003){ref-type="fig"}C,D). There was a significant reduction in phosphorylated STAT6 expression in TAM‐Rosa^creERT2^IL‐4Rα^−/lox^ mice and IL‐4Rα^−/−^ mice compared to OIL‐Rosa^creERT2^IL‐4Rα^−/lox^ mice.

![Prophylactic deletion of the IL‐4Rα impairs the induction of a T~H~2 cell--mediated cytokine and humoral response in allergic airway inflammation. T~H~2‐associated cytokine production in prophylactic ovalbumin (OVA) induced allergic asthma (as described in Figure [1](#all14137-fig-0001){ref-type="fig"}, A) was measured in ex vivo restimulated mediastinal lymph nodes (mLN) by ELISA. A, anti‐CD3 stimulated and B, OVA stimulated). C and D, Histogram showing impairment of pSTAT6 expression in OVA‐challenged mLN, lung tissue, and lung CD4^+^ T cells of ROSA^cre\ ERT2^IL‐4Rα^−/lox^ mice after induced gene deletion was evaluated by flow cytometry and represented as MFI expression histograms of pSTAT6 in the prophylactic model. Data representative mean ± SDs from one of two experiments (n = 5‐7). MFI, median fluorescence intensity; p‐STAT6, phosphorylated signal transducer and activator of transcription 6; FMO, fluorescence "minus" one. E, Antibody production in prophylactic depletion model; OVA‐specific IgG~1~, IgG~2a,~ and IgE; F, Total IgE. Data show mean ± SDs from 1 representative experiment of 3 independent experiments carried out (n = 5). Significant differences are described as: \**P* \< .05, \*\**P* \< .01, \*\*\**P* \< .001](ALL-75-1347-g003){#all14137-fig-0003}

We then assessed the effect of temporal IL‐4Rα deletion on humoral responses by measuring serum titers of OVA‐specific IgG~1~, IgG~2a~, IgE (Figure [3](#all14137-fig-0003){ref-type="fig"}E) and total IgE (Figure [3](#all14137-fig-0003){ref-type="fig"}F). There was significantly reduced OVA‐specific IgG~1~, IgE, and total IgE in TAM‐Rosa^creERT2^IL‐4Rα^−/lox^ mice when compared to OIL‐Rosa^creERT2^IL‐4Rα^−/lox^ mice, indicating a reduction of type‐2 associated antibody secretion by B cells. These results correlate with a reduction in AHR, mucus secretion, and allergic lung inflammation, when IL‐4Rα was temporally deleted prior to challenge with OVA. Taken together, these results demonstrate that temporally deletion of IL‐4Rα has a profound effect on induction of T~H~2 type allergic airway responses in sensitized mice and in subsequent disease development.

3.4. Deletion of IL‐4Rα signaling after established allergic airway disease reduces AHR and airway inflammation {#all14137-sec-0021}
---------------------------------------------------------------------------------------------------------------

We assessed the temporal requirement of IL‐4Rα signaling in a therapeutic model as described in Figure [1](#all14137-fig-0001){ref-type="fig"}A. Firstly, we assessed lung function and observed a significant reduction in airway resistance and elastance in TAM‐Rosa^creERT2^IL‐4Rα^−/lox^ compared to OIL‐Rosa^creERT2^IL‐4Rα^−/lox^ littermate controls (Figure [4](#all14137-fig-0004){ref-type="fig"}A). We also observed significantly increased resistance and elastance in OVA‐challenged OIL‐treated Rosa^creERT2^IL‐4Rα^−/lox^ when compared to PBS‐challenged control mice. This demonstrated a protective therapeutic effect of IL‐4Rα temporal deletion in established allergic airway disease.

![Therapeutic deletion of the IL‐4Rα reduces airway hyperresponsiveness and allergic airway inflammation. Mice (ROSA^cre\ ERT2^IL‐4Rα^−/lox^) were sensitized with ovalbumin (OVA)/Alum on days 0, 7, and 14 challenged with OVA on days 23‐25, fed (tamoxifen) TAM or OIL on days 27 to 30 by oral gavage, and then challenged with OVA on days 34‐36. Analysis was done on day 37. A, Airway resistance and airway elastance measured with increasing doses of methacholine (0‐40 mg/mL). B, Total bronchoalveolar lavage fluid cells. C, Total lung cells. D, Total number of neutrophils (CD11c^low^CD11b^high^Ly6G^high^) and eosinophils (CD11c^low^ CD11b^high^ Ly6G^low^ SiglecF^hi^) in the BALF were stained and analyzed by flow cytometry. E, Histology analyses of lung sections (magnification ×200), stained with hematoxylin and eosin (H&E) (bottom) and periodic acid‐Schiff (PAS) (top). F, Automated quantification of the area (μm^2^) of mucus staining per analyzed bronchiole epithelial lining was carried out using NIS elements imaging software. Shown is means ± SDs from one representative experiment of 3 independent experiments (n = 5‐8). Significant differences are described as \**P* \< .05, \*\**P* \< .01, \*\*\**P* \< .001](ALL-75-1347-g004){#all14137-fig-0004}

We then measured total infiltrating cells in BAL fluid and found that they were reduced in TAM‐Rosa^creERT2^IL‐4Rα^−/lox^ mice compared to OIL‐Rosa^creERT2^IL‐4Rα^−/lox^ mice (Figure [4](#all14137-fig-0004){ref-type="fig"}B), although the difference in lung tissue was not significant (Figure [4](#all14137-fig-0004){ref-type="fig"}C). This correlated with a reduction in airway eosinophilia in BAL fluid of TAM‐Rosa^creERT2^IL‐4Rα^−/lox^ mice compared to the OIL‐Rosa^creERT2^IL‐4Rα^−/lox^ mice (Figure [4](#all14137-fig-0004){ref-type="fig"}D). Global IL‐4Rα‐deficient mice had significantly higher neutrophilic infiltration in the BAL fluid when compared to TAM‐Rosa^creERT2^IL‐4Rα^−/lox^ mice, which correlated with increased total cell counts in this group (Figure [4](#all14137-fig-0004){ref-type="fig"}B‐D). When analyzing lung pathology by histology, we observed reduced mucus hypersecretion (Figure [4](#all14137-fig-0004){ref-type="fig"}E,F) and lung inflammation (Figure [4](#all14137-fig-0004){ref-type="fig"}E) in TAM‐Rosa^creERT2^IL‐4Rα^−/lox^ mice compared to OIL‐Rosa^creERT2^IL‐4Rα^−/lox^. These data, together with AHR, suggested that IL‐4Rα signaling is crucial in maintaining allergic airway inflammation in established disease.

3.5. T~H~2 immune response and antibody production is maintained after temporal deletion of IL‐4Rα signaling in established allergic airway disease {#all14137-sec-0022}
---------------------------------------------------------------------------------------------------------------------------------------------------

We demonstrated that temporal deletion of IL‐4Rα during the effector stage reduced AHR and lung inflammation. We then measured T~H~2 cytokines in mLNs stimulated with anti‐CD3 (Figure [5](#all14137-fig-0005){ref-type="fig"}A) or OVA (Figure [5](#all14137-fig-0005){ref-type="fig"}B). Interestingly, T~H~2 cytokine (IL‐4 and IL‐5) levels were similar between TAM‐Rosa^creERT2^IL‐4Rα^−/lox^ and OIL‐Rosa^creERT2^IL‐4Rα^−/lox^ mice in both anti‐CD3 (Figure [5](#all14137-fig-0005){ref-type="fig"}A) and OVA‐stimulated (Figure [5](#all14137-fig-0005){ref-type="fig"}B) mLNs. We then assessed humoral responses by measuring levels of OVA‐specific antibodies and total IgE. We observed no reduction in OVA‐specific IgG~1~ and IgG~2a~ (Figure [5](#all14137-fig-0005){ref-type="fig"}C), although a significant reduction in total IgE was observed (Figure [5](#all14137-fig-0005){ref-type="fig"}D) along with a slight reduction in OVA‐specific IgE (Figure [5](#all14137-fig-0005){ref-type="fig"}C) when comparing TAM‐Rosa^creERT2^IL‐4Rα^−/lox^ mice and OIL‐Rosa^creERT2^IL‐4Rα^−/lox^ mice. Taken together, these data suggested that the reduced signs of allergic airway inflammation and AHR during temporal deletion of IL‐4Rα were unlikely to be caused by reduced type‐2 cytokines.

![Therapeutic deletion of the IL‐4Rα has a maintained T~H~2 cell--mediated cytokine response even with reduced airway inflammation. T~H~2‐associated cytokine production in therapeutic ovalbumin (OVA) induced allergic asthma was measured in ex vivo restimulated mediastinal lymph nodes (mLNs) by using ELISA. A, anti‐CD3 stimulated and B, OVA stimulated. C, Antibody production in prophylactic depletion model; C, OVA‐specific IgG~1~, IgG~2a,~ and IgE. D, Total IgE. Data show mean ± SDs from 1 representative experiment of 3 independent experiments carried out (n = 5). Significant differences are described as: \**P* \< .05, \*\**P* \< .01, \*\*\**P* \< .001](ALL-75-1347-g005){#all14137-fig-0005}

Functionally distinct DCs are central in not only inducing, but also suppressing T~H~2 or T~H~17 immune response through secretion of T~H~ cell--polarizing cytokines.[34](#all14137-bib-0034){ref-type="ref"}, [35](#all14137-bib-0035){ref-type="ref"}, [36](#all14137-bib-0036){ref-type="ref"}, [37](#all14137-bib-0037){ref-type="ref"}, [38](#all14137-bib-0038){ref-type="ref"} We investigated the DC compartment in lung draining LNs (Figure [6](#all14137-fig-0006){ref-type="fig"}A,B). We observed a reduction in migratory CD11b^+^ DCs in both prophylactic (Figure [6](#all14137-fig-0006){ref-type="fig"}C) and therapeutic (Figure [6](#all14137-fig-0006){ref-type="fig"}D) IL‐4Rα temporarily deleted TAM‐Rosa^creERT2^IL‐4Rα^−/lox^ mice compared to the OIL‐Rosa^creERT2^IL‐4Rα^−/lox^ mice. These migratory DCs are implicated in trafficking of antigens to the lymphoid tissue during sensitization and induction of a T~H~2 cell--mediated response.[38](#all14137-bib-0038){ref-type="ref"} These results suggest a possible necessity of IL‐4Rα signaling in trafficking of CD11b^+^ DCs for establishing T~H~2 cell--mediated inflammation in allergic airway disease.

![The dendritic cell compartment was altered with temporal depletion of the IL‐4Rα gene. A, A representative gating strategy for migratory dendritic cells (DCs) (CD11c^+^MHCII^hi^) and residential DCs (CD11c^+^MHCII^int^) in mLNs stained by flow cytometry. B, gating strategy of the CD103^+^ migratory DCs and CD11b^+^ migratory DCs. C, Plotted mean ± SDs proportions of migrated cell populations following ovalbumin (OVA) airway exposure in a prophylactic model. D, Plotted mean ± SDs proportions of migrated cell populations following OVA airway exposure in a therapeutic model. Significant differences among groups are represented as (\**P* \< .05, \*\**P* \< .01, \*\*\**P* \< .001)](ALL-75-1347-g006){#all14137-fig-0006}

3.6. T~H~17‐induced neutrophilia is dependent on IL‐4Rα deletion prior to sensitization {#all14137-sec-0023}
---------------------------------------------------------------------------------------

We observed airway neutrophilia in IL‐4Rα^−/−^ mice, but not in TAM‐Rosa^creERT2^IL‐4Rα^−/lox^ mice in both prophylactic and therapeutic deletion of IL‐4Rα signaling (Figures [2](#all14137-fig-0002){ref-type="fig"}D and [4](#all14137-fig-0004){ref-type="fig"}D). We showed previously that increased production of IL‐17, after disruption of IL‐4Rα expression on CD4^+^ T cells, was responsible for increased IL‐17 production and airway neutrophilia.[11](#all14137-bib-0011){ref-type="ref"} IL‐17 levels were measured in supernatants of ex vivo anti‐CD3 (Figure [7](#all14137-fig-0007){ref-type="fig"}A,C) and OVA restimulated mLNs (Figure [7](#all14137-fig-0007){ref-type="fig"}B,D) in both prophylactic (Figure [7](#all14137-fig-0007){ref-type="fig"}A,B) and therapeutic models (Figure [7](#all14137-fig-0007){ref-type="fig"}C,D). IL‐17 was found to be increased in IL‐4Rα^−/−^ mice, but not in TAM‐Rosa^creERT2^IL‐4Rα^−/lox^ mice (Figure [7](#all14137-fig-0007){ref-type="fig"}A‐D). Additionally, IFN‐γ was increased significantly in IL‐4Rα^−/−^ mice compared to the other groups in the prophylactic model and anti‐CD3 stimulated mLNs of prophylactic model mice (Figure [7](#all14137-fig-0007){ref-type="fig"}A‐D), further confirming that the anti‐T~H~2 effect observed in the TAM‐Rosa^creERT2^IL‐4Rα^−/lox^ was IFN‐γ‐independent. However, IFN‐γ release was similar in mLNs stimulated with OVA of the IL‐4Rα^−/−^ and TAM‐Rosa^creERT2^IL‐4Rα^−/lox^ mice (Figure [7](#all14137-fig-0007){ref-type="fig"}D). We further investigated a possible DC compartment responsible for the consequential T~H~17 response (Figure [6](#all14137-fig-0006){ref-type="fig"}A and [6](#all14137-fig-0006){ref-type="fig"}). There was increased migratory CD103^+^ DCs in mLN of IL‐4Rα^−/−^ mice compared to TAM‐Rosa^creERT2^IL‐4Rα^−/lox^ and OIL‐Rosa^creERT2^IL‐4Rα^−/lox^ mice in both prophylactic (Figure [6](#all14137-fig-0006){ref-type="fig"}C) and therapeutic (Figure [6](#all14137-fig-0006){ref-type="fig"}D) models. CD103^+^ DCs have been shown to control T~H~17 polarization by secreting polarizing cytokines IL‐23 and IL‐2.[38](#all14137-bib-0038){ref-type="ref"}, [39](#all14137-bib-0039){ref-type="ref"} We also found increased levels of IL‐23 and IL‐2 in OVA‐restimulated mLNs in IL‐4Rα^−/−^ mice compared to TAM‐Rosa^creERT2^IL‐4Rα^−/lox^ mice in the prophylactic model (Figure [7](#all14137-fig-0007){ref-type="fig"}E). In a therapeutic model, IL‐4Rα^−/−^ mice showed an increase in IL‐2 and IL‐23 which was significant compared to the other groups, except for TAM‐treated mice (Figure [7](#all14137-fig-0007){ref-type="fig"}F). We further validated our findings by temporal deletion of IL‐4Rα before sensitization (Figure [S2](#all14137-sup-0003){ref-type="supplementary-material"}A). We observed increased BAL fluid neutrophilia, mLN CD103^+^ migratory DCs, IL‐17, and IL‐23 in TAM‐Rosa^creERT2^IL‐4Rα^−/lox^ mice when compared to OIL‐Rosa^creERT2^IL‐4Rα^−/lox^ mice (Figure [S2](#all14137-sup-0003){ref-type="supplementary-material"}B‐E), a phenotype similar to what we observe in a global knockout mice. These results highlight a potential involvement of migratory CD103^+^ DCs together with IL‐23 in maintaining expansion of T~H~17 cells observed in IL‐4Rα deletion prior to sensitization. Our approach of temporal IL‐4Rα chain deletion supports a critical role in establishment and maintenance of disease and further highlights its therapeutic potential in many asthma disease endotypes.

![Prophylactic and therapeutic deletion of IL‐4Rα reduces a T~H~17‐associated cytokine response. T~H~1‐ and T~H~17‐associated cytokine production levels were measured in ex vivo restimulated mediastinal lymph nodes (mLNs) by using ELISA in both models. A, Prophylactic anti‐CD3 stimulated and B, ovalbumin (OVA) stimulated cytokine (IL‐17 and IFN‐γ) production. C, Therapeutic anti‐CD3 stimulated and D, OVA‐stimulated cytokine (IL‐17 and IFN‐γ) production. E, OVA stimulated cytokine (IL‐2 and IL‐23) production in prophylactic model and F, in therapeutic model. Data show mean ± SDs from 1 representative experiment of 3 independent experiments. Significant differences are shown as: \**P* \< .05, \*\**P* \< .01, \*\*\**P* \< .001](ALL-75-1347-g007){#all14137-fig-0007}

4. DISCUSSION {#all14137-sec-0024}
=============

The critical importance of IL‐4/IL‐13 axis as a driver of T~H~2 immunity in allergic asthma has been established with IL‐4Rα being central mediator of disease pathology.[1](#all14137-bib-0001){ref-type="ref"}, [4](#all14137-bib-0004){ref-type="ref"} We and others have previously demonstrated cell‐specific function of IL‐4Rα signaling in the development of allergic disease.[1](#all14137-bib-0001){ref-type="ref"}, [11](#all14137-bib-0011){ref-type="ref"}, [16](#all14137-bib-0016){ref-type="ref"}, [18](#all14137-bib-0018){ref-type="ref"}, [19](#all14137-bib-0019){ref-type="ref"}, [20](#all14137-bib-0020){ref-type="ref"}, [21](#all14137-bib-0021){ref-type="ref"}, [40](#all14137-bib-0040){ref-type="ref"} However, the temporal role of IL‐4Rα signaling in vivo, during sensitization and effector phases of allergic disease, is not completely clear. In this study, we developed an inducible IL‐4Rα deletion model, allowing us to conditionally delete receptor signaling. Using this approach, we were able to investigate the role of IL‐4/IL‐13 signaling during onset and effector phase of OVA‐induced allergic airway disease in systemically sensitized animals. Our findings show that temporal deletion of IL‐4Rα signaling postsensitization prevents development of OVA‐induced AHR, eosinophilia, and goblet cell hyperplasia (summarized in Table [S1](#all14137-sup-0003){ref-type="supplementary-material"}). Hence, abrogation of IL‐4Rα signaling should have significant therapeutic benefit for T~H~2‐type allergic asthma. Our study contributes to already existing literature on the central role of IL‐4Rα subunit in allergic asthma and may guide currently ongoing phase III clinical trials targeting IL‐4Rα in various asthma endotypes.

IL‐4Rα signaling is important in establishing a T~H~2‐driven allergic airway pathology, and its absence, for example, IL‐4Rα‐deficient mice, leads to amelioration of IL‐4/IL‐13‐dependent allergic airway disease.[41](#all14137-bib-0041){ref-type="ref"}, [42](#all14137-bib-0042){ref-type="ref"}, [43](#all14137-bib-0043){ref-type="ref"} We observed a reduction in AHR, eosinophilia, mucus hypersecretion, and pathology during temporal deletion of IL‐4Rα after sensitization phase or during effector phase. This indicates that anti‐IL‐4Rα therapies may be suitable for therapeutic treatment of acute allergic disease patients and possibly prophylactic intervention in asymptomatic, but sensitized patients, who represent 50%‐60% of asthma patients[44](#all14137-bib-0044){ref-type="ref"}, [45](#all14137-bib-0045){ref-type="ref"} and are highly at risk of developing asthma or eczema.[46](#all14137-bib-0046){ref-type="ref"}, [47](#all14137-bib-0047){ref-type="ref"}

We further showed that the diminished T~H~2 cell response in our study is not caused by an increased IFN‐*γ* response as previously suggested.[48](#all14137-bib-0048){ref-type="ref"} The reduction in T~H~2 responses in our study correlated with reduced STAT6 phosphorylation.[43](#all14137-bib-0043){ref-type="ref"} Of significant note is the potential requirement for IL‐4Rα signaling in migration of CD11b^+^ DCs to secondary lymphoid tissues for antigen sensitization and priming of a T~H~2 cell--mediated immune response. This would be consistent with previous studies showing ILC2‐derived IL‐13 being important in priming migration of DC to mediastinal lymph nodes through CCL21 chemoattractant.[49](#all14137-bib-0049){ref-type="ref"} It is also possible that IL‐4Rα in DC is crucial for recruitment of memory T~H~2 cells to the lung through production of chemokines such as CCL17.[38](#all14137-bib-0038){ref-type="ref"}, [50](#all14137-bib-0050){ref-type="ref"} IL‐4 and IL‐13 have been shown to regulate chemokine production by DCs or macrophages[51](#all14137-bib-0051){ref-type="ref"}, [52](#all14137-bib-0052){ref-type="ref"} and monocyte‐derived DCs have been implicated in being predominant chemokine producers, which are known to regulate migration of T~H~2 cells.[38](#all14137-bib-0038){ref-type="ref"} This modulation of the DC compartment suggests an additional diverse mechanism involved in augmenting allergic airway inflammation with the temporal deletion of IL‐4Rα signaling postallergen sensitization.

Deletion of the IL‐4Rα subunit after established T~H~2 disease shows a reduction in OVA‐induced AHR and airway inflammation despite a persistent T~H~2 cytokine production. This is suggestive of a maintained T~H~2 memory cell recall from systemic OVA sensitization which is IL‐4/IL‐13 independent.[53](#all14137-bib-0053){ref-type="ref"}, [54](#all14137-bib-0054){ref-type="ref"}, [55](#all14137-bib-0055){ref-type="ref"}, [56](#all14137-bib-0056){ref-type="ref"} This is in contrast to a similar temporal deletion of IL‐4Rα signaling prior to secondary infection with *Nippostrongylus brasiliensis* showing a recall role in driving type‐2 immune responses and clearance of the parasites.[33](#all14137-bib-0033){ref-type="ref"} In this helminth infection model, IL‐4Rα signaling is vital in not only initiating, but also maintaining a functional T~H~2‐driven pathology and its associated cytokines. However, we show evidence that IL‐4Rα signaling is not necessary for restimulation of a new T~H~2 cell response in allergic airway disease. This is consistent with previous studies where blocking IL‐4/IL‐13 axis after an established T~H~2 response with an antagonist did not affect ongoing cytokine production by IL‐4‐secreting CD4^+^ T cells.[56](#all14137-bib-0056){ref-type="ref"} Recently, using single‐cell RNA sequencing, it was shown that basal stem cells from nasal epithelial polyps have a strong IL‐4/IL‐13 memory signature that persists even after dupilumab treatment.[57](#all14137-bib-0057){ref-type="ref"} This stem cell memory may be what drives disease persistence especially in established T~H~2 airway responses.

The successful utility of targeting IL‐4Rα signaling has led to clinical trials for dupilumab, a human monoclonal antibody for anti‐T~H~2 therapy in allergic asthma patients and atopic dermatitis.[12](#all14137-bib-0012){ref-type="ref"}, [13](#all14137-bib-0013){ref-type="ref"}, [58](#all14137-bib-0058){ref-type="ref"} Concern arises on unprecedented T~H~1/T~H~17 polarizing inflammation with anti‐T~H~2 interventions in humans and mice.[4](#all14137-bib-0004){ref-type="ref"}, [24](#all14137-bib-0024){ref-type="ref"}, [25](#all14137-bib-0025){ref-type="ref"}, [27](#all14137-bib-0027){ref-type="ref"}, [59](#all14137-bib-0059){ref-type="ref"}, [60](#all14137-bib-0060){ref-type="ref"} Our mouse model clears a T~H~2 response without inducing any potential T~H~1/T~H~17 responses even with established disease, thus emphasizing on a potential benefit of anti‐IL‐4Rα therapies as a viable T~H~2 treatment option. Conversely, Stat6‐deficient or IL‐4Rα‐deficient mice have shown increased IgG~2a~ and IgG~2b~ secretion even with resolution of T~H~2 inflammation.[4](#all14137-bib-0004){ref-type="ref"}, [59](#all14137-bib-0059){ref-type="ref"} Recently, Rorγt‐deficient T cells were shown to suppress T~H~2 and T~H~17 differentiation via upregulated BCL6 expression in the airways.[61](#all14137-bib-0061){ref-type="ref"} Bcl6, a transcriptional repressor which antagonizes both Rorγt and Gata3,[62](#all14137-bib-0062){ref-type="ref"}, [63](#all14137-bib-0063){ref-type="ref"} is high in IL‐4‐committed T follicular helper (Tfh) cells, a precursor of T~H~2 cells upon secondary antigen challenge.[64](#all14137-bib-0064){ref-type="ref"} The anti‐T~H~2 outcome observed with Rorγt deficiency in T cells [61](#all14137-bib-0061){ref-type="ref"} could be a result of impaired Tfh developmental plasticity to develop into effector T cells.[64](#all14137-bib-0064){ref-type="ref"} It is likely that temporal deletion of IL‐4Rα on T cells might disrupt Tfh cell responses during sensitization phase, preventing their IL‐4 commitment into effector T~H~2 cells.[63](#all14137-bib-0063){ref-type="ref"}

Development of T~H~17 responses has been suggested as a potential detrimental side‐effect of anti‐allergic therapies targeting the IL‐4/IL‐13/IL‐4Rα signaling pathway.[65](#all14137-bib-0065){ref-type="ref"} The exact mechanism of how the T~H~17 response is potentiated is elusive. In our previous work, we have shown that disruption of IL‐4Rα‐signaling specifically on CD4^+^ T cells results in antigen‐specific T~H~17 responses after allergic sensitization.[11](#all14137-bib-0011){ref-type="ref"} Similar to the global IL‐4Rα knockout mice, deficiency of IL‐4Rα subunit on CD4^+^ T cells was prior to sensitization. In this study, T~H~17 responses were only observed in global IL‐4Rα‐deficient mice, but not in TAM‐Rosa^creERT2^IL‐4Rα^−/lox^ mice, where IL‐4Rα signaling was disrupted only after sensitization. Additionally, with the observed long‐lasting effects of embryonic deletion of IL‐4Rα and that of "conditional" knockout of IL‐4Rα at presensitized period, the protective effect against challenge with allergen could be due to the protective effect against IL‐13 because of the deleted IL‐4Rα signaling. This is further seen in the therapeutic model where in the presence of a residual IL‐13 production, the protective effect against IL‐13 still remains with an observed diminished airway hyperresponsiveness. Thus, our study supports the concept that IL‐4Rα signaling directly prevents differentiation of CD4^+^ T cells into T~H~17 cells during allergen sensitization and reveals a temporal IL‐4Rα dependency in development of a T~H~17 airway inflammation. Strikingly, with the absence of IL‐4Rα signaling prior to sensitization, we observed a modulation of a DC compartment in lymphoid tissue. A predominant increase migratory CD103^+^ DC profile and antigen‐specific IL‐23 secretion were observed and are both known to be responsible for maintenance of memory T~H~17 cells.[66](#all14137-bib-0066){ref-type="ref"} Shalaby et al similarly revealed pathogenic T~H~17 cells in airway inflammation which was mainly driven by cDC IL‐23. However, their model relied on environmental adjuvants (HDM and LPS) driving a TLR4‐dependent co‐stimulation with OVA to expand or maintain chronic airway inflammation.[39](#all14137-bib-0039){ref-type="ref"}

In conclusion, we provide further evidence for a therapeutic potential for blocking IL‐4Rα signaling in acute disease cases as well as prophylactic possibility in cases of asymptomatic atopic patients in T~H~2‐type allergic airway inflammatory responses.

CONFLICTS OF INTEREST {#all14137-sec-0026}
=====================

The authors declare that they have no conflicts of interest.

AUTHOR CONTRIBUTIONS {#all14137-sec-0027}
====================

FB, FK, and SH conceived and supervised study. JK, SH, FK, and MS performed the experiments. JK, SH, FK, and FB analyzed the data. JK, SH, FK, and FB wrote the paper. All authors discussed the results and commented on the manuscript.

Supporting information
======================

###### 

 

###### 

Click here for additional data file.

###### 

 

###### 

Click here for additional data file.

###### 

 

###### 

Click here for additional data file.

We thank the UCT Research Animal Facility for maintaining mice, Munadia Ansari for genotyping mice, and Amkele Ngomti for assistance. We are grateful to Lizette Fick for excellent histology services. We thank Michelle Epstein (Medical University Vienna) for critically reading the manuscript.
